

1 **Intervention strategies for cystinuria: A systematic review**

2

3 Nirmal P. Bhatt^{1,2}, Aniruddh V. Deshpande^{2,3,4}, Bernadette Jones-Freeman¹, Simon H. Jiang^{5,6,7}, Malcolm
4 R. Starkey^{1,2*}.

5

6 ¹Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne,
7 Victoria, Australia

8 ²Priority Research Centre GrowUpWell, The Faculty of Health and Medicine and Hunter Medical
9 Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia

10 ³Centre for Kidney Research, Children's Hospital at Westmead, New South Wales, Australia

11 ⁴Urology Unit, Department of Surgery, Children's Hospital at Westmead, Sydney, New South Wales,
12 Australia

13 ⁵Department of Immunology and Infectious Diseases, Australian National University, Canberra ACT,
14 Australia,

15 ⁶Centre for Personalized Immunology, John Curtin School of Medical Research, Australian National
16 University, Canberra ACT, Australia

17 ⁷Department of Nephrology, The Canberra Hospital, Canberra ACT, Australia

18

19 *Correspondence: malcolm.starkey@monash.edu

20

21 **Key Words:** Cystinuria, cystine, cystine stone, intervention

22

23

24

25

26

27 **Abstract (245 words)**

28 **Purpose:** This systematic review evaluates the current intervention strategies for cystinuria and assesses
29 their quality and efficacy in order to determine the need to identify new and improved strategies for
30 treatment.

31
32 **Materials and Methods:** A literature search for interventions in cystinuria was conducted on key
33 electronic databases for studies published between 1996 and 2019. Quality was assessed using
34 Methodological Index for Non-Randomized Studies (MINORS). Studies meeting the inclusion criteria
35 were assessed for study design, patient characteristics and outcomes of interventions, including urinary
36 cystine levels, stone-free rate and stone recurrence rate. A qualitative and critical analysis was performed.

37
38 **Results:** Common treatment strategies for cystinuria include hydration and diuresis, alkali therapy and
39 thiol-based therapeutics. Conservative therapies such as adequate hydration and urinary alkalization
40 effectively increased urinary pH, decreased urinary cystine levels and the formation of cystine stones.
41 Second line agents reported included thiols such as Tiopronin, D-penicillamine and captopril. Non-
42 invasive surgical procedures were found to reduce operative trauma and preserved renal function.
43 Combined treatment approaches with hydration and thiols after surgical procedures were associated with
44 less stones and reduced stone recurrence rates. Patient compliance to interventions was often poor and
45 contributed to recurrent cystine stones.

46
47 **Conclusions:** Despite existing pharmacological intervention strategies, cystinuria patients frequently
48 require surgical procedures. A more detailed understanding of the mechanisms of pathogenesis of
49 cystinuria as well as an evaluation of patients on an individual basis may be beneficial in reducing the
50 severity of cystinuria, by reducing stone recurrence and associated renal complications.

51 INTRODUCTION

52 Cystinuria is a rare inherited autosomal recessive disease. The estimated overall prevalence of cystinuria
53 is 1 in 7,000 births globally, ranging from 1 in 2,500 in Jewish Israelis and 1 in 100,000 in Sweden¹⁻³
54 Cystinuria accounts for approximately 1-2% of all kidney stone cases in adults and 3-8% in pediatrics.⁴⁻⁸
55 Cystinuria is characterized by defects in the transport of cystine and other dibasic amino acids including
56 lysine, arginine, and ornithine in both the proximal renal tubules and the small intestine. This defect in
57 transportation result in the accumulation of cystine, which precipitates and forms cystine stones.⁹ Cystine
58 stones in the kidney and urinary tract, cause inflammation and obstruction and can predispose an
59 individual to the development of chronic kidney disease.

60
61 Cystinuria commonly affects children, and the early age of onset, as well as the high stone
62 recurrence rate, in addition to poor compliance with existing interventions, makes this condition difficult
63 to manage.^{10, 11} Cystinuria is classified into three subtypes denoted type A, type B and type AB. Type A,
64 is caused by mutations in the solute carrier family 3 member 1 (*SLC3A1*) gene encoding the neutral and
65 basic amino acid transport protein (rBAT) heavy subunit.^{12, 13} Type B, is caused by mutations in the solute
66 carrier family 7 member 9 (*SLC7A9*) gene encoding the light subunit b^{0,+} type amino acid transporter 1
67 (b^{0,+}AT).^{13, 14} Type AB occurs when mutations in both *SLC3A1* and *SLC7A9* genes are present.¹³ All three
68 types of cystinuria cause defective reabsorption of cystine and dibasic amino acids by the proximal renal
69 tubule.

70
71 Despite the recent developments in the understanding of the genetic causes of cystinuria,^{13, 15, 16}
72 there is a lack of effective interventions and currently no cure for the disease. Mainstay treatments focus
73 on maintaining cystine homeostasis in the urine. Traditionally, cystinuria management focuses on urinary
74 alkalization using potassium citrate, sodium bicarbonate as well as limiting animal protein intake, whilst

75 maintaining fluid intake to increase urinary volume.^{17, 18} There are currently very limited randomized
76 controlled trials (RCTs) in cystinuria patients that have assessed stone-related outcomes more than 1 year
77 after intervention. Most of the existing studies report combined intervention approaches such as hydration
78 and diuresis and alkali therapy, as well as pharmacological and surgical interventions.

79

80 The thiol-based therapeutics alpha-mercaptopropionylglycine (α -MPG or tiopronin), D-
81 penicillamine and captopril are established pharmacological interventions for cystinuria.^{17, 19} Complicated
82 stones may require surgical procedures such as extracorporeal shockwave lithotripsy (ESWL),
83 percutaneous nephrolithotomy (PCNL), ureterorenoscopy (URS), retrograde intrarenal surgery (RIRS)
84 and open surgery (OP) to remove cystine stones.^{10, 11, 20} This review evaluates the existing interventions
85 strategies for cystinuria.

86 **MATERIALS AND METHODS**

87 **Literature search**

88 A literature search was conducted on key electronic databases including Medline, Embase, Cochrane,
89 Web of Science, Scopus and Google Scholar. English language articles published between 1996 and
90 December 2019 were included. Manual searching of key journals and conference proceedings were
91 performed to retrieve any additional relevant articles. The following search terms were used individually
92 or in combination; cystinuria, cystine stone, cystine calculi, cystine urolithiasis, cystine nephrolithiasis,
93 cystine, kidney, cystine urine and cystinuria patient. The search terms were defined based on the PICO
94 definition; P (population), I (intervention), O (outcomes), while C (comparison) was only applied where
95 placebo-control and internal-control available in the literature.

96

97 **Inclusion and exclusion criteria**

98 A diagnosis of cystinuria was based on clinical investigation with at least one previous/current episode of
99 cystine stones, urine cystine levels >250-300mg/L and patients being treated with alkalinizing, or
100 pharmacological agents or surgical procedures. The primary outcomes were the type of intervention,
101 change in urinary pH levels, change in urinary cystine levels, stone-free and stone recurrence rates. There
102 were no exclusions based on age, gender, ethnicity, or geographical location. Due to the lack of RCTs for
103 this rare disease, analysis was largely restricted to non-randomized studies with or without control arms.
104 Observational studies including case-control, retrospective and prospective studies were included.
105 Conference abstracts and papers were included if there was sufficient data, and corresponding authors
106 contacted to obtain full study details. Review articles, editorials, news, letters, comments, case series and
107 case reports were excluded. Review articles were used for cross-referencing to retrieve any missing
108 studies and did not contribute to the final number of articles. The inclusion and exclusion criteria were
109 independently applied to all identified articles. Two authors participated in the initial screening of titles

110 and abstracts, and independently screened the titles and abstracts before assessing full text articles. Any
111 disputes were resolved by multiple author agreement. We contacted the authors of the primary reports to
112 request any unclear or unpublished data. If the authors did not reply, the available data was used.

113

114 **Data Extraction**

115 This systematic review follows Preferred Reporting Items for Systematic Reviews and Meta-Analysis
116 (PRISMA) guidelines.²¹ References from the database search were pooled into Endnote X8 reference
117 software. Selected data were assessed for study design, aims, inclusion criteria, patient characteristics,
118 intervention strategy and outcomes, renal function data, length of follow-up, stone-free rates, and stone
119 recurrence rates. Intervention studies included alkali therapy, pharmacological agents and surgical
120 procedures outcome comparison at least pre- and post-treatment. The study protocol was registered with
121 PROSPERO to guide this systematic review (ID: CRD42020152061).

122

123 **Risk of bias (quality) assessment**

124 Most of the available quality assessment tools are designed for the evaluation of RCTs, case-control or
125 cohort studies. Here, the methodological quality assessment tool, Methodological Index for Non-
126 Randomized Studies (MINORS), was used to assess the studies that met the inclusion criteria. MINORS
127 is validated tool applied for the methodological quality of non-comparative and comparative
128 observational studies.²² It consists of 8 items for non-comparative and an additional 4 items for
129 comparative studies. The quality assessment were performed independently by 2 authors (NPB and MRS).
130 AVD, BJF and SHJ cross-checked the selected literature and quality assessment tool to resolve any
131 disputes.

132

133

134 **Data synthesis**

135 Due to the anticipated variability in the included studies, and lack of RCTs, meta-analysis was not
136 planned. Hence a qualitative and critical analysis of the data was performed with available patient
137 characteristics, disease history, and treatment procedures and effectiveness. Post-treatment outcomes as
138 mentioned above were compared with patient's history.

139

140 **RESULTS**

141 **Search results**

142 The initial database and Google search retrieved a total of 1445 articles. After excluding duplicate studies,
143 660 studies were reviewed for title and abstract screening. 594 were excluded due to being non-relevant
144 (500), a review (34), case reports (48), animal studies (4), supplementary comments (3), non-English (2)
145 or published prior to 1996 (3). A total of 66 studies underwent full-text review. 40 articles were excluded
146 after screening the full text; non-relevant studies (20), inappropriate study aims or outcomes (15) or full
147 text not available (5). 24 studies met the review criteria and the MINORS quality assessment tool was
148 applied to these studies, which resulted in the exclusion of 2 studies that did not meet the quality control
149 requirements (Figure 1).

150

151 **Study characteristics**

152 A summary of the study characteristics is provided in Table 1. 17 studies were retrospective observational
153 studies and 7 were prospective observational studies, with or without comparison groups. Of the 24 total
154 studies, 11 were non-comparative studies and 13 were comparative studies. The quality of the included
155 studies were assessed using the MINORS score (Table 2 and 3). The mean score for non-comparative

156 studies was 11 out of 16 (range, 8-13). For non-comparative studies MINORS scores are classified as:
157 low (score 5-8), moderate (score 9-12), and high quality (score 13-16). The mean score for comparative
158 studies was 17 out of 24 (range, 12-21). For comparative studies MINORS scores are classified as: low
159 (score 7-12), moderate (score 13-18) and high quality (score 19-24). Those studies that scored a moderate
160 or high MINORS score were included. 2 studies were excluded due to a low MINORS score.

161

162 Of the 24 studies, 18 reported outcomes from alkalinizing compounds (potassium citrate and
163 sodium bicarbonate) and/or thiol drugs (D-penicillamine, tiopronin and captopril).^{10, 11, 17-20, 23-34} 20 studies
164 reported outcomes from surgical interventions in cystinuria patients.^{10, 11, 17-20, 24-26, 29, 30, 32-40} Of the 24
165 studies, 15 reported combined intervention methods with alkalinizing compounds, pharmacological drugs
166 and/or surgical procedures.^{10, 11, 17-20, 24-27, 29, 30, 32-34} No studies directly compared pharmacological
167 intervention to surgical intervention.

168

169 In this review, a total of 654 cystinuria patients (mean 27.25 per study) were included. Among
170 these patients, 323 were male (53%) and 286 (47%) were female, from 21 studies. 3 studies did not
171 distinguish patient's gender. 19 studies reported mean patient age, which ranged from 7.4 to 49 years.<sup>10,
172 17-20, 23-28, 31, 32, 34-38, 40</sup> Of the 24 studies, 5 reported median patient age, which ranged from 6 to 18.5 years.<sup>11,
173 29, 30, 33, 39</sup>

174

175 **Effectiveness of urine dilution and alkalization**

176 Initial treatment for cystinuria is to maintain daily urine volume >3L/day.¹⁷ In addition to appropriate
177 hydration, urinary alkalization is used to maintain urinary pH >6.5.¹⁸ Of the 24 studies, 16 reported the
178 use of potassium citrate and sodium bicarbonate as an alkalizing agents for the management of
179 cystinuria.^{10, 11, 17-20, 24-27, 29-34} 5 studies reported the detail concentration of alkalizing agents used and their

180 outcome of treatment (Table 4).^{11, 17, 18, 26, 32} Potassium citrate (1mEq/kg/day,^{11, 30} 40-70mmol/day,¹⁸
181 1000mg three times/day³²) and sodium bicarbonate (8-18gm/kg/day,¹⁷ 47.6-107mmol/day,¹⁸ 500mg four
182 times/day³²) were recommended for all patients after cystinuria diagnosis. A significant increase in
183 urinary pH was observed with sodium bicarbonate treatment (6.4-7.25, $p<0.01$),¹⁸ and potassium citrate
184 treatment (6.4-7.10, $p<0.05$),¹⁸ (5.6-6.9, $p=0.02$)¹¹ and (5.8-7.55, $p<0.001$).²⁶ Post-treatment urinary pH
185 levels were increased >7 with treatment of potassium citrate and sodium bicarbonate.^{17,32}

186

187 Cystinuria patients excrete less citrate ($262\pm 428\text{mg}/1.73/\text{m}^3$) than healthy controls
188 ($491\pm 490\text{mg}/1.73/\text{m}^3$, $p=0.044$) with urinary citrate excretion in the pre-treatment group lower
189 ($255\pm 219\text{mg}/1.73/\text{m}^3$) than the post-treatment group ($729\pm 494\text{mg}/1.73/\text{m}^3$, $p=0.003$).¹¹ Urinary citrate
190 excretion was also increased by alkalization therapy (2.9 ± 1.1 - $5.4\pm 1.3\text{mmol}/\text{day}$, $p<0.01$).¹⁷

191

192 Urinary sodium excretion was significantly increased ($144\text{mmol}/\text{day}$ - $220\text{mmol}/\text{day}$, $p<0.05$)¹⁸
193 and ($173\pm 58\text{mmol}/\text{day}$ - $263\pm 91\text{mmol}/\text{day}$, $p<0.001$)¹⁷ by sodium bicarbonate treatment. Urinary
194 potassium excretion ($63\text{mmol}/\text{day}$ - $94\text{mmol}/\text{day}$, $p<0.01$) were also significantly increased during
195 treatment with potassium citrate.¹⁸

196

197 **Effectiveness of pharmacological interventions**

198 17 studies reported pharmacological intervention using the thiol-based drugs; tiopronin, D-penicillamine
199 and captopril.^{10, 11, 17-20, 23-25, 27-34} These interventions were applied when hydration and alkalization
200 treatment was not effective in reducing urinary pH and cystine levels. Of the 17 studies, 12 reported
201 urinary pH change, urinary cystine levels, number of stones per patient-year and stone free rate (Table
202 5).^{11, 17, 19, 23-25, 27-32}

203

204 7 studies reported an association between pharmacological interventions and urinary cystine
205 excretion, along with additional outcomes such as the number of stone episodes, the number of surgical
206 procedures, stone recurrence rate and stone-free rate.^{11, 17, 23, 24, 27, 28, 31} Urinary cystine decreased from
207 1,052±161mg/day to 755±81mg/day with tiopronin treatment, and from 789±126mg/day to
208 517±92mg/day with D-penicillamine in the mean patients age of 19.6 years. However, captopril did not
209 change cystine excretion (1,044±57mg/day to 1,039±137mg/day).¹⁷ A significant difference was reported
210 between patients treated with hyperdiuresishyper-diuresis and alkalization, and added thiols
211 (808±305mg/24hrs vs 585±128mg/24hrs, $p=0.046$).¹⁷ The average urinary cystine levels were reduced by
212 54% (range, 5-81%) with D-penicillamine (20mg/kg/day),²³ and 15% of cystinuria patients maintained
213 urinary cystine excretion <300mg/L following tiopronin (1000mg/day) treatment.³¹ Further, two studies
214 reported a significant reduction in urinary cystine levels ($p=0.015$)¹¹ and ($p<0.039$)²⁸ following
215 intervention with tiopronin and/or D-penicillamine. Decreased urine cystine level (221.2±75.2mg/L) was
216 reported when stone events <0.3 per year compared to increased urine cystine level (303.3±93.5mg/L)
217 when stone events ≥ 0.3 per year).²⁷ Cystinuria patients had less urinary citrate excretion compared to the
218 control group (262±428mg/1.73/m3-491±490mg/1.73/m3, $p=0.044$), however, citrate excretion was
219 increased ($p=0.003$) after intervention with tiopronin (10-15mg/kg/day).¹¹

220
221 Cystinuria patients with alkalization and thiol intervention had up to a 65% reduction in yearly
222 stone events, which equated to 2.7 per patient or 0.52 stone events per patient-year.¹⁹ Tiopronin (13.8-
223 51mg/kg/day) and D-penicillamine (16.3-17.8mg/kg/day) reduced stone events from 0.28 to 0.03 per
224 year.²⁴ Stone free rates ranged from 22 to 87% with diuresis, alkalization and pharmacological
225 management after single or multiple surgical procedures.^{11, 17, 19, 25, 27, 29, 30, 32} Thiol-treated patients had
226 decreased stone recurrence when urinary cystine excretion was maintained at <797 mg/gm creatinine/24
227 hours.²⁵

228
229
230
231
232
233
234
235
236
237
238
239

Effectiveness of surgical interventions

Surgical intervention strategies for cystine stones include ESWL, PCNL, URS, RIRS and OP. Either single or combined surgical procedures were partially effective in removing stones.^{10, 11, 17-20, 24-26, 29, 30, 32-40} Ahmed *et al.* reported cystine stone patients needed repeated surgical procedures to remove stones including ESWL which accounted for 61%, URS 21%, PCNL 12% and OP 6% of surgical procedures.¹⁰ Another study reported ESWL 26%, PCNL 12%, RIRS 6% and OP 53% surgical procedures were required to remove cystine stones.¹⁷ Typically, males required more surgical procedures than females (2.9 vs 2.5).³²

240
241
242
243
244
245
246
247
248

Of the 20 studies, 13 reported detail about intervention type, stone position, intervention procedure, stone free rate and stone recurrence rate (Table 6).^{10, 11, 17, 19, 20, 25, 29, 30, 32, 33, 36, 38, 39} The type of surgical treatment selected was dependent on the size and location of the stones. 5 studies reported various stone positions from unilateral, bilateral, left and right kidney, calyceal, pelvic and ureteral cystine stones.^{17, 19, 30, 32, 33} Bilateral cystine stones were associated with a higher number of lifetime stone surgeries than unilateral stones (6.5 vs 2 sessions, $p<0.05$).³³ Stones were found in the left (46%) and right (54%) kidney.³⁰ Furthermore, 41% calyceal, 55% ureter and 4% pelvic stones were present in patients with cystinuria.³²

249
250
251
252

Stone events were 2.4,¹⁷ 3.2,³² 4.2¹⁰ and 5.5¹⁹ per patient for the treatment period in 4 studies. Total surgical procedures ranged from 0.84 to 7.9 per patient.^{10, 17, 19, 25, 29, 32, 33, 36, 39} Further surgical procedures varied from 0.29 to 1 per patient-year in 6 studies.^{11, 17, 19, 33, 38, 39} 67% of cystinuria patients had

253 their stones removed after a single or combined ESWL, PCNL and OP intervention, and 33% still had
254 residual stones even after surgery. The overall stone recurrence rate was 0.64 per patient-year.¹¹ There
255 were no differences between less-invasive and traditional surgical procedures with surgical procedures
256 per patient-year (1.34 vs 1.16) and stone recurrence rate (0.111 vs 0.493), respectively.³⁸

257
258 10 studies reported the percentage of stone-free patients after the first surgical procedures which
259 varied from 22% to 100%.^{10, 11, 17, 19, 20, 25, 30, 32, 36} Stone-free rate was dependent on the type of intervention
260 used; PNCL (85%) was more successful than other procedures, however, stone free status was not linked
261 to probability of recurrence of stones.²⁵ Stone free rate after first PCNL was 0% in cystine stone group
262 and 40% in struvite stone group, and final stone free rate after a secondary procedure was increased to 70%
263 in cystine stone group and 80% in struvite stone group.⁴⁰ RIRS had a 100% stone free rate and it was
264 considered a safe intervention in pediatric cystine stone management.²⁰

265
266 5 studies reported pharmacological interventions and stone recurrence in cystinuria patients,
267 which ranged from 31 to 78%.^{11, 17, 25, 29, 30} Overall stone recurrence was 41.1% during mean follow-up
268 period of 2.5 years and recurrence rate was decreased to 16.6% for medical prophylaxis, although, 100%
269 recurrence for non-prophylaxis cystinuria patients.²⁶ Stone recurrence was 3.2 per patient during the 5
270 years of follow-up and number of surgical intervention was 2.7 per patient.³² The recurrence rate after
271 achieving stone-free status with surgical treatment was 31.2%, and the regrowth rate for children with
272 residual stones was 29.4%.³⁰ Moore *et al.*, reported 62.5% of cystinuria patients had recurring stones
273 during the mean follow-up period of 8.6 years and lower stone recurrence rate in patients who had stone-
274 free status following their first treatment compared to stone-free status following multiple sessions
275 ($p=0.091$).²⁹

276

277 **Comparison between cystine and non-cystine stone patients**

278 4 studies reported comparisons between cystine and non-cystine patients (Table 7).^{34, 35, 37, 40}
279 Cystine stones occurred in early age compared to calcium oxalate (CaOx) stones (15.0±11.1years vs
280 33.5±14.8years, $p<0.001$), and were larger in size compared with CaOx stones (24.6±11.0mm vs
281 15.2±8.25mm, $p<0.001$).³⁷ 2 studies reported cystine stone patient required higher surgical procedures
282 than CaOx stone patients (14.1% vs 2.96%, $p=0.007$ ³⁵ and 9.80±9.17 vs 2.73±1.95, $p<0.001$ ³⁷). Cystine
283 stone patients underwent significantly more surgical procedures than non-cystine stone patients (4.0 vs
284 1.86, $p<0.001$).³⁴ Similar findings were reported by Yamacake *et al.*, where cystine stone patients
285 required higher surgical procedures than struvite stone patients (3.57±1.04 vs 2.0±1.22, $p=0.028$).⁴⁰

286
287 The average number of surgical procedures in cystinuria patients was 3.1 (range 1-8/patient).²⁹
288 Thiol intervention decreased the number of required surgical procedures from 0.88 to 0.23 ($p<0.001$)
289 during the follow-up period.³⁴ Furthermore, SWL (1.18±1.56 and 0.73±1.02, $p=0.0001$), PCNL
290 (0.93±1.18 and 0.09±0.47, $p=0.00001$) and OP (0.92±1.21 and 0.16±0.55, $p=0.0001$) procedures were
291 reported for cystine stone than CaOx stone patients.³⁵ Similar findings were reported by Sfoungaristos *et*
292 *al.*, with cystinuria patients more frequently receiving SWL (6.33±6.63 vs 1.63±1.73, $p<0.001$) and PCNL
293 (1.53±1.41 vs 0.37±0.49, $p<0.001$) than CaOx stone patients.³⁷ Overall the number of surgical procedures
294 to remove stones was higher in cystine stone patients than CaOx stone patients (9.80±9.17 vs 2.73±1.95,
295 $p<0.001$).³⁷

298 **Patient compliance and treatment outcomes**

299 The management and outcomes of cystinuria patients depends on patient compliance. 3 studies reported
300 patient compliance with follow-up protocols based on their diet, medication regimen and frequency of
301 patient visits to the clinic/doctor following intervention.^{32, 36, 37} Medical compliance after the diagnosis of

302 cystine stones was 64.3% and overall success of the treatment was 64.2%.³² A monthly, quarterly and
303 semi-annual clinic visit was required for medical evaluation of cystinuria patients, and stone-free rates
304 were higher (73%) in patients that were compliant to treatment compared to non-compliant patients
305 (33%).³⁶ The average number of surgical interventions was 1.0 in compliant patients compared to 4.0 in
306 non-compliant patients ($p<0.05$).³⁶ The average serum creatinine (1.02mg/dL vs 1.1mg/dL, $p=0.32$) and
307 urinary cystine excretion ($282.2\pm 52.6\text{mg/L}$ vs $382.4\pm 61.3\text{mg/L}$, $p=0.25$), and urinary pH (7.4 ± 0.2 vs
308 7.1 ± 0.3 , $p=0.66$) were different for compliant and non-compliant cystinuria patients.³⁶ There were lower
309 compliance rates to diet (30 vs 62.5%) and medical treatment (64.3 vs 85.7%) for cystine stone patients
310 compared with CaOx stone patients.³⁷ Cystinuria patient compliance was associated with side effects of
311 pharmacological agents and surgical procedures.³⁷

312

313 **DISCUSSION**

314 In this systematic review, we synthesized the results from the observational studies of existing
315 intervention approaches for cystinuria including hydration and diuresis, alkalization, pharmacological and
316 surgical procedures. The initial management of cystinuria patients includes hydration and urine
317 alkalization to decrease urinary cystine levels to $<250\text{-}300\text{mg/L}$. Fluid intake should maintain urine
318 volume $>3\text{L/day}$. Potassium citrate and sodium bicarbonate can then be used to increase urine pH >6.5 ,
319 and cystine excretion to $<250\text{mg/L}$.^{11, 18} Additional pharmacological interventions are introduced if
320 cystinuria patients do not respond to hydration and alkalization therapy. These additional interventions
321 typically include treatment with tiopronin, D-penicillamine and captopril.¹⁹ Pharmacological treatments
322 are effective in lowering urinary cystine levels ultimately decreasing stone events, stone recurrence rate,
323 and increasing stone free rates in cystinuria patients.^{11, 17, 19, 23-25, 27-29, 31} While alkalization and
324 pharmacological interventions are somewhat effective at decreasing stone episodes, these interventions
325 are often poor at reducing cystine stone recurrence. Therefore, cystinuria patients often require surgical
326 interventions to decrease stone recurrence rates and stone growth. To maintain a stone-free status,

327 combined approaches of thiol-drugs and surgical procedures are required.^{10, 11} Multiple studies report that
328 cystinuria patients require significantly higher numbers of surgical interventions than other urinary stone
329 patients.^{34, 35, 37, 40} A greater number of ESWL, PCNL and OP procedures were required for cystine stones
330 than CaOx stones and patients were at increased risk for renal impairment and loss of renal function.^{35, 37}
331 PCNL was the most successful surgical procedure for achieving stone-free status in cystinuria patients.²⁵
332 PCNL is also a safe and effective treatment for children with cystine stones.³⁰ Although existing
333 interventions are useful for reducing cystine stones, patient compliance with pharmacological medications
334 is poor due to adverse side effects and high recurrence rates of cystine stones. Hence, management of
335 cystine stones requires improved intervention approaches to reduce stone recurrence rates.³⁸

336

337 Current treatment strategies for cystinuria are focused on relieving symptoms and preventing the
338 formation of cystine stones. It is accepted that increasing fluid intake, regular monitoring of urinary pH
339 and reduced dietary methionine and salt intake can reduce urinary cystine concentration.⁴¹ This can be
340 achieved by high fluid consumption that increases urine volume to wash out cystine crystals, and
341 alkalinizing supplements that maintain urine pH >6.5 to inhibit cystine aggregation and reduce cystine
342 stone development.¹⁸ Usually, cystine is poorly soluble between pH 5-6.5 and cystine stones formed when
343 individual cystine excretion in urine is exceeding 240-300mg/L (1.33-1.66mmol/L).¹ Therefore, urine pH
344 of >6.5 may help the dissolution of stones.¹⁸ Hence, urinary pH must be routinely monitored. Hydration
345 and alkalization therapies prescribed according to body weight and severity of disease may improve
346 quality of life of cystinuria patients by controlling urinary cystine concentration.

347

348 Thiol-based drugs are capable of breaking the disulfide bond of cystine producing cysteine, which
349 is more soluble in urine and inhibits stone formation.¹ These thiol drugs combine with cystine to form a
350 soluble disulfide complex that prevents stone formation and promotes stone dissolution. Tiopronin, D-

351 penicillamine and captopril are the most commonly reported thiol drugs for cystine stone management.
352 Tiopronin has been shown to have high efficacy and less side effects compared with D-penicillamine and
353 captopril.^{42, 43} D-penicillamine is equally effective, although tiopronin has a lower incidence of side
354 effects compared to D-penicillamine. Typically, 75-100mg captopril is effective in patients who are non-
355 responsive to standard treatment and in associated hypertensive cystinuria patients, but does increase the
356 risk of worsening chronic kidney disease.⁴¹ Approximately 50% of cystinuria patients experience adverse
357 effects to these medications including gastrointestinal intolerance, nephrotic syndrome, rash and
358 leukopenia, which impacts on patient compliance to these interventions.⁴¹

359
360 Surgical interventions for cystine stones are the same as those considered for other urinary
361 stones,⁴¹ although those experiencing cystine stones are more likely to undergo surgical interventions
362 more often due to the higher rate of reoccurrence.^{35, 40} The most common surgical interventions that are
363 recommended for cystinuria include ESWL, PCNL, URS, RIRS and OP. ESWL is an effective treatment
364 for cysteine stones smaller than 2.5 cm whereas PCNL is most useful for larger stones.⁴⁴ During the
365 surgical interventions, ESWL increased stone free rates in cystinuria patients, however, it is still lower
366 than non-cystine stone patients.³⁴ Due to the composition of cystine stones and the amino acid structure,
367 most of patient require multiple ESWL to dissolve of the stones. ESWL is effective and less invasive
368 treatment of cystinuria preventing long-term complications of recurrent cystine stones.⁴⁵ On the other
369 hand, PCNL is considered a better surgical treatment of larger cystine stones where ESWL is less
370 effective. However, PCNL is improved with ureteroscopic design and can be considered for larger and
371 more complex stones. To achieve high stone-free rates, the majority of stones can be treated by ESWL,
372 PCNL, URS, RIRS or OP alone or in combination.^{11, 44} URS is minimally invasive procedure usually
373 done when ureter is examined for stone identification and this procedure is effective to observe cystine
374 stone during blockage or stone pass out through urinary tract.³⁹ URS is very safe and effective for
375 recurrent cystine stone to perform precise surgical intervention to stone clearance.⁴⁶ Most studies suggest

376 RIRS is the most commonly used procedure and is a safe operative intervention. RIRS is effective,
377 minimally invasive, safe treatment procedure in pediatric with 100% stone free rate.²⁰ Usually, RIRS is
378 used as an initial procedure more often in children, whereas ESWL and PCNL are more common
379 procedures in adults.⁴⁷ OP is restricted to when ESWL, PCNL, URS, RIRS alone or combined are not
380 effective. OP procedures are recommended for complex staghorn and multiple stones, where other
381 treatment strategies fail. PCNL and RIRS are safe and effective treatment procedures for pediatric cystine
382 stone patients.^{20, 30}

383
384 This review has several limitations, including the heterogeneity among selected studies including
385 sample size and the short follow up time of the selected studies. Typically, RCTs are selected for
386 systematic reviews because of their validity and strong outcomes. In this review, half of the available
387 literature are retrospective studies without a control group. Due to the lack of RCTs studies in cystinuria,
388 owing to the condition being rare, this review included all interventional studies having meaningful
389 outcomes. Serum cystine levels and urinary cystine levels were not available for all included studies.
390 Indeed, further RCTs are required for assessing the effectiveness of interventions in cystinuria.

391
392 **CONCLUSIONS**
393 This systematic review highlights that cystinuria is a challenging disease to treat, requiring a range and/or
394 combination of intervention strategies including hydration, alkalization, pharmacological and surgical
395 procedures. Cystinuria patients have a high rate of cystine stone recurrence. New emerging therapies
396 based on a more detailed understanding of cystinuria pathogenesis and treatment should focus to reducing
397 recurrent stones, decreasing side effects, and preservation of renal function. The currently available
398 observational studies do not have enough interventional details and long-term (>1 year) follow up, and
399 most contain retrospective data without control groups. RCTs with long-term follow up and large sample

400 size would be the appropriate design to obtain clear outcomes for optimal treatment strategies for
401 cystinuria. The future successful management of cystinuria patients will require improved strategies for
402 patient compliance and better treatment outcomes.

403

404 **REFERENCES**

- 405
- 406 1. Knoll T, Zöllner, A, Wendt-Nordahl G et al: Cystinuria in childhood and adolescence:
407 recommendations for diagnosis, treatment, and follow-up. *Pediatric nephrology (Berlin, Germany)*
408 2005; **20**: 19.
- 409 2. Pereira DJ, Schoolwerth A C, Pais VM: Cystinuria: current concepts and future directions. *Clin*
410 *Nephrol* 2015; **83**: 138.
- 411 3. Weinberger A, Sperling O, Rabinovitz M et al: High frequency of cystinuria among Jews of
412 Libyan origin. *Hum Hered* 1974; **24**: 568.
- 413 4. Chillaron J, Font-Llitjos M, Fort J et al: Pathophysiology and treatment of cystinuria. *Nat Rev*
414 *Nephrol* 2010; **6**: 424.
- 415 5. Andreassen KH, Pedersen KV, Osther SS et al: How should patients with cystine stone disease be
416 evaluated and treated in the twenty-first century? *Urolithiasis* 2016; **44**: 65.
- 417 6. Milliner DS, Murphy ME: Urolithiasis in pediatric patients. *Mayo Clin Proc* 1993; **68**: 241.
- 418 7. Mandel NS, Mandel GS: Urinary Tract Stone Disease in the United States Veteran Population. II.
419 Geographical Analysis of Variations in Composition. *Journal of Urology* 1989; **142**: 1516.
- 420 8. Leusmann DB, Blaschke R, Schmandt W: Results of 5035 Stone Analyses: A Contribution to
421 Epidemiology of Urinary Stone Disease. *Scandinavian Journal of Urology and Nephrology* 1990;
422 **24**: 205.
- 423 9. Thomas K, Wong K, Withington J et al: Cystinuria-a urologist's perspective. *Nat Rev Urol* 2014;
424 **11**: 270.
- 425 10. Ahmed K, Khan MS, Thomas K et al: Management of cystinuric patients: an observational,
426 retrospective, single-centre analysis. *Urologia Internationalis* 2008; **80**: 141.
- 427 11. Tekin A, Tekgul S, Atsu N et al: Cystine calculi in children: The results of a metabolic evaluation
428 and response to medical therapy. *J Urol* 2001; **165**: 2328-2330.

- 429 12. Calonge MJ, Gasparini P, Chillarón J et al: Cystinuria caused by mutations in rBAT, a gene
430 involved in the transport of cystine. *Nature Genetics* 1994; **6**: 420.
- 431 13. Dello SL, Pras E, Pontesilli C et al: Comparison between SLC3A1 and SLC7A9 cystinuria
432 patients and carriers: a need for a new classification. *J Am Soc Nephrol* 2002; **13**: 2547.
- 433 14. Feliubadaló L, Font M, Purroy J et al: Non-type I cystinuria caused by mutations in SLC7A9,
434 encoding a subunit (bo,+AT) of rBAT. *Nature Genetics* 1999; **23**: 52.
- 435 15. Wong KA, Mein R, Wass M et al: The genetic diversity of cystinuria in a UK population of
436 patients. *BJU Int* 2015; **116**: 109
- 437 16. Shen L, Cong X, Zhang X et al: Clinical and genetic characterization of Chinese pediatric cystine
438 stone patients. *J Pediatr Urol* 2017; **13**: 629.e1-629.e5.
- 439 17. Barbey F, Joly D, Rieu P et al: Medical treatment of cystinuria: Critical reappraisal of long-term
440 results. *Journal of Urology* 2000; **163**: 1419.
- 441 18. Fjellstedt E, Denneberg T, Jeppsson J-O et al: A comparison of the effects of potassium citrate
442 and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. *Urological
443 research* 2001; **29**: 295.
- 444 19. Chow GK, Strem SB: Medical treatment of cystinuria: results of contemporary clinical practice.
445 *J Urol* 1996; **156**: 1576-1578.
- 446 20. Yuruk E, Tuken M, Gonultas S et al: Retrograde intrarenal surgery in the management of
447 pediatric cystine stones. *Journal of pediatric urology* 2017; **13**: 487.e1-487.e5.
- 448 21. Moher D, Shamseer L, Clarke M et al: Preferred reporting items for systematic review and meta-
449 analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**: 1.
- 450 22. Slim K, Nini E, Forestier D et al: Methodological index for non-randomized studies (minors):
451 development and validation of a new instrument. *ANZ J Surg* 2003; **73**: 712.
- 452 23. DeBerardinis RJ, Coughlin CR, Kaplan, P: Penicillamine therapy for pediatric cystinuria:
453 experience from a cohort of American children. *Journal of Urology* 2008; **180**: 2620.

- 454 24. Dello SL, Laurenzi C, Legato A et al: Cystinuria in children and young adults: success of
455 monitoring free-cystine urine levels. *Pediatric Nephrology* 2007; **22**: 1869.
- 456 25. Chow GK, Stroom SB: Contemporary urological intervention for cystinuric implications patients:
457 immediate and long-term impact and implications. *J Urol* 1998; **160**: 341-345.
- 458 26. Izol V, Aridogan IA, Karsli O et al: The effect of prophylactic treatment with Shohl's solution in
459 children with cystinuria. *Journal of pediatric urology* 2013; **9**: 1218.
- 460 27. Koichiro A, Kenichi E, Takeshi U et al: The long-term outcome of cystinuria in Japan. *Urol Int*
461 1998; **61**: 86-89.
- 462 28. Malieckal DA, Modersitzki F, Mara K et al: Effect of increasing doses of cystine-binding thiol
463 drugs on cystine capacity in patients with cystinuria. *Urolithiasis* 2019; **13**: 13.
- 464 29. Moore SL, Somani BK, Cook P: Journey of a cystinuric patient with a long-term follow-up from
465 a medical stone clinic: necessity to be SaFER (stone and fragments entirely removed).
466 *Urolithiasis* 2019; **47**: 165.
- 467 30. Onal B, Dogan C, Citgez S et al: Percutaneous nephrolithotomy in children with cystine stone:
468 long-term outcomes from a single institution. *J Urol* 2013; **190**: 234.
- 469 31. Pietrow P, Auge BK, Weizer AZ et al: Durability of the medical management of cystinuria. *J*
470 *Urol* 2003; **169**: 68.
- 471 32. Shim M, Park HK: Multimodal treatments of cystine stones: an observational, retrospective
472 single-center analysis of 14 cases. *Korean Journal of Urology* 2014; **55**: 515.
- 473 33. Usawachintachit M, Sherer B, Hudnall M et al: Clinical outcomes for cystinuria patients with
474 unilateral versus bilateral cystine stone disease. *J Endourol* 2018; **32**: 148.
- 475 34. Worcester EM, Coe FL, Evan AP et al: Reduced renal function and benefits of treatment in
476 cystinuria vs other forms of nephrolithiasis. *BJU International* 2006; **97**: 1285.
- 477 35. Assimos DG, Leslie SW, Christopher N et al: The impact of cystinuria on renal function. *The*
478 *Journal of urology* 2002; **168**: 27.

- 479 36. Pareek G, Steele TH, Nakada SY: Urological intervention in patients with cystinuria is decreased
480 with medical compliance. *J Urol* 2005; **174**: 2250.
- 481 37. Sfoungaristos S, Hakim R, Katz R et al: Cystine stones: A single tertiary center experience.
482 *Journal of Endourology* 2015; **29**: 357.
- 483 38. Trinchieri A, Montanari E, Zanetti G et al: The impact of new technology in the treatment of
484 cystine stones. *Urological Research* 2007; **35**: 129.
- 485 39. Varda BK, Johnson EK, Johnson KL et al: Imaging and surgical utilization for pediatric
486 cystinuria patients: A single-institution cohort study. *Journal of pediatric urology* 2016; **12**:
487 106.e1.
- 488 40. Yamacake KGR, Marchini GS, Reis S et al: The challenge of cystine and struvite stone formers:
489 clinical, metabolic and surgical assessment. *International Braz J Urol* 2016; **42**: 977.
- 490 41. Biyani CS, Cartledge JJ: Cystinuria—Diagnosis and Management. *EAU-EBU Update Series*
491 2006; **4**: 175.
- 492 42. Rhodes HL, Yarram-Smith L, Rice SJ et al: Clinical and genetic analysis of patients with
493 cystinuria in the United Kingdom. *Clin J Am Soc Nephrol* 2015; **10**: 1235.
- 494 43. Daudon M, Cohen-Solal F, Barbey F et al: Cystine crystal volume determination: a useful tool in
495 the management of cystinuric patients. *Urological Research* 2003; **31**: 207.
- 496 44. Cranidis AI, Karayannis AA, Delakas DS et al: Cystine stones: The efficacy of percutaneous and
497 shock wave lithotripsy. *Urologia Internationalis* 1996; **56**: 180.
- 498 45. Katz G, Kovalski N, Landau EH: Extracorporeal shock wave lithotripsy for treatment of
499 ureterolithiasis in patients with cystinuria. *British journal of urology* 1993; **72**: 13.
- 500 46. Ruggera L, Zanin M, Beltrami P et al: Retrograde transureteral approach: a safe and efficient
501 treatment for recurrent cystine renal stones. *Urological Research* 2011; **39**: 411.
- 502 47. Azili MN, Ozcan F, Tiryaki T: Retrograde intrarenal surgery for the treatment of renal stones in
503 children: Factors influencing stone clearance and complications. *Journal of Pediatric Surgery*
504 2014; **49**: 1161.




Table 1. Summary of the study characteristics

Study reference (alphabetical) and study type	Number of patients (male (M) and Female (F)) and mean or median age (years)	Interventions (%)	Follow-up period (years)	Total number of stone episodes and/or surgical interventions	Stone episodes per patient and/or stones per patient-year and/or stone recurrence per patient-year	Total surgical procedures per patient and/or per patient-year	Stone-free after treatment (%)	Therapy successful (Yes/Partially)
Ahmed <i>et al.</i> 2006 Retrospective observational	30 (16M and 14F) cystinuria patients Mean age = 39	21 (80.7%) Potassium citrates, 17 (65.3%) Sodium bicarbonate, 11 (42.3%) D-penicillamine 143 (61%) ESWL, 28 (12%) PCNL, 50 (21%) URS and 16 (6%) OP	Mean = 6	126 stone episodes and 237 surgical procedures	4.2 stone episodes per patient	7.9 per patient	28/30 (93.3%)	Yes
Akakura <i>et al.</i> 1999 Retrospective observational	31 (22M and 9F) cystinuria patients Mean age = 33	Potassium/Sodium citrate, Sodium bicarbonate, 28 (90.3%) D-penicillamine and Tiopronin, 2 (6.5%) Captopril	Mean = 7.5	N/A	0.19 stones per patient-year	N/A	15 (48.4%)	Yes
Assimos <i>et al.</i> 2002 Prospective observational	85 (49M and 36F) cystinuria patients vs 3,964 (2,594M	ESWL, PCNL, OP	N/A	N/A	N/A	14.1% (cystinuria patients) and 2.96% (CaOx stone patients) procedures,	N/A	Yes

	and 1,370F) CaOx stone patients Cystinuria patients mean age = 42.6 CaOx stone patients mean age = 48.9					$p=0.007$		
Barbey <i>et al.</i> 2000 Retrospective observational	27 (12M and 15F) cystinuria patients Mean age = 19.6	5 (18.5%) Potassium citrate, 22 (81.4%) Sodium bicarbonate, (8 - 18gm/kg/day) D-penicillamine (600-1200mg/day), Tiopronin (500-1000mg/day), Captopril (100-150mg/day) 32 (25.6%) SWL, 15 (12%) PCNL, 7 (5.6%) RIRS and 65 (53.3%) OP	Mean = 11.6	66 stone episodes and 44 surgical procedures	2.4 stone episodes per patient and 0.20 stones per patient-year	1.5 per patient and 0.14 per patient-year	13 (48%)	Yes
Chow <i>et al.</i> 1996 Retrospective observational	16 (9M and 7F) cystinuria patients Mean age = 33.1	Potassium citrate, Sodium bicarbonate, D-penicillamine (1000-2000gm/day) or Tiopronin (800-1,200mg/day) in divided doses,	Mean = 6.5	88 stone episodes and 34 surgical procedures	5.5 stone episodes per patient and 0.84 stones per patient-year	2.1 per patient and 0.3 per patient-year	12/16 (75%)	Yes

		Captopril (50mg 3 times/day) 10.5% ESWL, 68.4% PNCL, 21% RIRS						
Chow <i>et al.</i> 1998 Retrospective observational	31 (14M and 17F) cystinuria patients Mean age = 33.8	Potassium citrate, Sodium bicarbonate, D-penicillamine (1000-2000gm/day) or Tiopronin (800-1,200 mg/day), Captopril (50mg 3 times day) 9 (14.8%) ESWL (stone <1.5 cm ²), 41 (67.2%) PCNL (stone > 1.5 cm ²), 7 (11.5%) RIRS, 4 (6.6%) PCNL+ESWL	Mean = 4.6	61 surgical procedures	N/A	1.98 per patient	52 (86.90%)	Yes
DeBerardinis <i>et al.</i> 2008 Retrospective observational	11 cystinuria patients Mean age = 7.4	D-penicillamine (5-20 mg/kg/day)	Mean = 9	N/A	N/A	N/A	N/A	Partially
Fjellstedt <i>et al.</i> 2001 Prospective observational	14 (8M and 6F) cystinuria patients Mean age = 21	13 Potassium citrate (60mmol/day), Sodium bicarbonate (71.4mmol/day), 10 Tiopronin (1250-3000mg/day) 7 ESWL	Mean = 0.1	N/A	N/A	N/A	N/A	Yes

Izol <i>et al.</i> 2013 Prospective case-control	17 (10M and 7F) cystinuria patients Mean age = 8.5	Potassium citrate and Citric acid SWL, PCNL	Mean = 2.5	N/A	N/A	N/A	N/A	Yes
Malieckal <i>et al.</i> 2019 Prospective observational	10 (7M and 3F) cystinuria patients Mean age = 49	3 (30%) D-penicillamine, 7 (70%) Tiopronin	N/A	N/A	N/A	N/A	N/A	Yes
Moore <i>et al.</i> 2018 Retrospective observational	16 (8M and 8F) cystinuria patients Median age = 15.5	Potassium citrate D-penicillamine (500mg twice a day) PCNL, SWL, URS	Mean = 8.6	N/A	62.5% of patients had recurrent stones	3.1 per patient	N/A	Yes
Onal <i>et al.</i> 2013 Retrospective observational	51 (29M and 22F) cystinuria patients Median age = 6	Potassium citrate or Potassium sodium hydrogen citrate (1mEq/kg), Tiopronin (10mg/kg) 11 (16.9%) SWL, 14 (21.5%) PCNL, 2 (3.1%) URS, 4 (6.1%) OP, 1 (1.5%) PCNL+OP	Median = 8	N/A	N/A	N/A	73.8%	Yes
Pareek <i>et al.</i> 2005 Retrospective observational	20 (6M and 14F) cystinuria patients Mean age =	5 vs 16 PCNL, 5 vs 15 Ureteroscopy, 1 vs 5 SWL in complaint and non-complaint patients	Mean = 3.5	N/A	N/A	1 (complaint) and 4 (non-complaint) per patient	8 (73%) complaint and 3 (33%) non-	Yes

	45						complaint	
Pietrow <i>et al.</i> 2003 Retrospective observational	26 (11M and 15F) cystinuria patients Mean age = 32	Tiopronin (1000mg/day)	Mean = 3.2	N/A	N/A	N/A	N/A	Partially
Shim <i>et al.</i> 2014 Retrospective observational	14 (8M and 6F) cystinuria patients Mean age = 19.6	9 (64.3%) Potassium citrate (1000 mg 3 times/day), Sodium bicarbonate (500mg 4 times/day), 3 (21.4%) D-penicillamine (250mg twice a day) 12 PNCL, 25 URS, 1 OP	Median = 5	38 surgical procedures	2.7 stone episodes per patient and 3.2 stone recurrences per patient-year	N/A	9 (64.2%)	Yes
Sfoungaristos <i>et al.</i> 2015 Retrospective case-control	30 (18M and 12F) cystinuria patients Cystinuria patients mean age = 45.6 CaOx stone patients mean age = 46	PCNL, ESWL, URS, RIRS	N/A	9.80±9.17 stone episodes for cystinuria patients and 2.73±1.95 for CaOx stone patients	N/A	N/A	N/A	Yes

Strologo <i>et al.</i> 2007 Prospective observational	20 cystinuria patients Mean age = 12.6	Potassium citrate, Sodium bicarbonate, Tiopronin (25 mg/kg/day), D-penicillamine (17mg/kg/day) PCNL, OP	Mean = 3.5	N/A	0.28 stones per patient-year	N/A	N/A	Yes
Tekin <i>et al.</i> 2001 Prospective case-control	18 (13M and 5F) cystinuria patients vs 24 (17M and 7F) healthy controls Median age = 6.5	Potassium citrate (1mEq/kg/day), Tiopronin (10-15mg/kg/day) 2 (11.1%) ESWL, 2 (11.1%) PCNL, 9 (50%) OP, 3 (16.6%) ESWL+OP, 2 (11.1%) ESWL+PCNL, 1 (5.55) URS	Median = 1.3	N/A	0.64 stones recurred per patient-year	N/A	12/18 (66.7%)	Yes
Trinchieri <i>et al.</i> 2007 Retrospective observational	Traditional cystinuria treatment group 31 (18M and 13F) vs less invasive cystinuria treatment group 17 (8M and 9F) Mean age = 37.2	PNCL, ESWL, OP	N/A	20.3 stone episodes in traditional and 12.1 stone episodes in less invasive treatment group	Stone recurrence per patient-year was 1.34 in traditional and 1.16 in less invasive surgical group	N/A	N/A	Yes

Usawachintachit <i>et al.</i> 2018 Retrospective case-control	42 (20M and 22F) cystinuria patients Median age = 18.5	36 (85.7%) Potassium citrate 11 (26.2%) Tiopronin, 2 (4.8%) D-penicillamine	Mean = 8.8	261 surgical procedures	N/A	5 per patient and 0.57 per patient-year	N/A	Yes
Varda <i>et al.</i> 2015 Retrospective observational	Median age = 12	13 PCNL, 44 URS, 16 ESWL, 3 OP	Median = 4.5	110 surgical procedures	6 stone episodes per patient and 1 stones per patient-year	N/A	N/A	Yes
Worcester <i>et al.</i> 2006 Prospective case-control	52 (24M and 28F) cystinuria patients vs 3215 non-cystine stone patients Cystinuria patients mean age = 34 Non-cystine stone patients mean age = 43	Potassium citrate 9 D-penicillamine or Captopril, 20 Tiopronin SWL	Mean = 4.3	N/A	N/A	3.2-4.8 (cystinuria patients) vs 0.60-1.16 (CaOx stone patients) per patient	N/A	Yes
Yamacake <i>et al.</i> 2016 Retrospective observational	8 (2M and 6F) cystinuria patients 8 (2M and 6F) struvite stone	Cystine stone: 7/8 PCNL, SWL and OP Struvite stone: 5/8 PCNL, SWL and OP	Cystinuria patients mean = 4.7 Struvite stone patients mean = 3.3	N/A	N/A	3.0 (cystinuria) and 2.2 (struvite stone patient) per patient	70% (cystine stone) and 80% (struvite stone)	Yes

	patients Mean age = 24.7							
Yuruk <i>et al.</i> 2017 Retrospective observational	14 cystinuria patients Mean age = 10.9	Potassium citrate, Tiopronin RIRS	Mean = 2.1	N/A	N/A	N/A	100%	Yes

SWL/ESWL, extracorporeal shockwave lithotripsy; PCNL, percutaneous nephrolithotomy; RIRS, retrograde intrarenal surgery; URS, ureterorenoscopy; OP, open surgery; CaOx, calcium oxalate; N/A, not available

Table 2. Quality assessment for non-comparative studies

Study Items	<i>Ahmed et al.</i> 2006	<i>Barbey et al.</i> 2000	<i>Chow et al.</i> 1996	<i>Chow et al.</i> 1998	<i>DeBerardinis et al.</i> 2008	<i>Onal et al.</i> 2013	<i>Shim et al.</i> 2014	<i>Strologo et al.</i> 2007	<i>Verda et al.</i> 2015	<i>Worcester et al.</i> 2006	<i>Yuruk et al.</i> 2017
A clearly stated aim	2	2	2	2	2	2	2	2	2	2	2
Inclusion of consecutive patients	2	2	2	2	2	2	2	2	2	2	2
Prospective collection of data	0	2	1	1	0	1	1	1	1	1	2
Endpoints appropriate to the aim of the study	2	2	1	2	2	1	2	2	1	2	2
Unbiased assessment of the study endpoint	1	1	1	1	1	1	1	1	1	2	1
Follow-up period appropriate to the aim of the study	2	2	2	2	2	2	2	2	2	2	2
Loss of follow-up less than 5%	2	1	2	2	1	1	1	1	2	2	2
Prospective calculation of the study size	0	0	0	0	0	0	0	0	0	0	0
TOTAL SCORE (/16)	11	12	11	12	10	10	11	11	11	13	13
Study quality	M	M	M	M	M	M	M	M	M	H	H

H, High; M, Moderate; L, Low

Table 3. Quality assessment for comparative studies

Items \ Study	Akakura <i>et al.</i> 1999	Assimos <i>et al.</i> 2002	Fjellstedt <i>et al.</i> 2001	Izol <i>et al.</i> 2013	Maieckal <i>et al.</i> 2019	Moore <i>et al.</i> 2018	Pareek <i>et al.</i> 2005	Pietrow <i>et al.</i> 2003	Sfougari stos <i>et al.</i> 2015	Tekin <i>et al.</i> 2001	Trinchieri <i>et al.</i> 2007	Usawachi ntacht <i>et al.</i> 2018	Yamacak <i>et al.</i> 2016
A clearly stated aim	2	2	2	2	2	2	2	2	2	2	2	2	2
Inclusion of consecutive patients	2	2	2	2	2	2	2	2	2	2	2	2	2
Prospective collection of data	1	1	1	1	2	1	2	0	0	1	1	2	2
Endpoints appropriate to the aim of the study	2	2	1	2	2	2	2	2	2	2	2	2	2
Unbiased assessment of the study endpoint	2	1	2	1	2	2	2	1	2	2	2	1	1
Follow-up period appropriate to the aim of the study	2	0	1	2	0	2	2	2	0	1	0	2	1
Loss of follow-up less than 5%	2	0	1	2	0	2	2	1	2	2	0	2	2
Prospective calculation of the study size	0	0	0	0	0	0	0	0	1	0	0	0	0
An adequate control group	0	2	2	1	0	0	1	0	2	2	1	2	2
Contemporary groups	2	2	1	2	2	2	2	1	2	2	1	2	2
Baseline	1	1	1	1	2	2	2	2	2	1	1	2	2

equivalence of groups													
Adequate statistical analysis	1	2	2	1	1	2	2	2	2	1	2	2	1
TOTAL SCORE (/24)	17	15	16	17	15	19	21	15	19	18	14	21	19
Study quality	M	M	M	M	M	H	H	M	H	M	M	H	H

H, High; M, Moderate; L, Low

Table 4. Effectiveness of urine dilution and alkalinization

Study reference	Interventions	pH change	Stone recurrence %	Key outcomes
Barbey <i>et al.</i> 2006	Potassium citrate and sodium bicarbonate (8-18gm/kg/day)	7.5	78	Increased urinary pH and reduced urinary cystine levels
Fjellstedt <i>et al.</i> 2001	Potassium citrate and sodium bicarbonate (40-70mmol/day and 47.7-107mmol/day)	6.4-7.10, $p<0.05$ (potassium citrate) and 6.4-7.25, $p<0.01$ (sodium bicarbonate)	NR	In the absence of severe renal impairment, alkalinization significantly increases urinary pH levels
Izol <i>et al.</i> 2013	Potassium citrate and citric acid (2mmol/kg per day in 3 divided doses)	5.8 ± 0.5 - 7.5 ± 0.4 , $p<0.001$	41	Increased urinary pH and reduced stone recurrence rate
Shim <i>et al.</i> 2014	Potassium citrate and sodium bicarbonate (1000mg 3 times/day and 500mg 4 times/day)	6.5-7.2	NR	Increased urinary pH levels
Tekin <i>et al.</i> 2014	Potassium citrate (1mEq/kg/day)	5.6 ± 0.2 - 6.9 ± 0.3 , $p=0.020$	33	Increased urinary pH and decreased urinary citrate excretion

Table 5. Effectiveness of pharmacological interventions

Study reference	Interventions	pH change	Urinary cystine levels	No. of stones per patient-year	Stone-free %	Key outcomes
Akakura <i>et al.</i> 1999	Tiopronin, D-penicillamine, captopril	NR	221.2±75.2mg/L	0.19	48	Decreased urinary cystine levels and lower stone events per year
Barbey <i>et al.</i> 2000	Tiopronin (500-1000mg/day), D-penicillamine (600-1200mg/day), captopril (100-150mg/day)	7.5	No thiols 808±305mg/24 hours and 585±128mg/24 hours with thiols, <i>p</i> =0.046	0.20	22	Decreased urinary cystine levels and stone recurrence rate
Chow <i>et al.</i> 1996	Tiopronin (800 to 1,200mg/day, D-penicillamine (1000-2000gm/day), captopril (50 mg 3 times/day)	>7.5	771mg/24 hours	0.84	75	65% of cystinuria patients had decreased stone formation
Chow <i>et al.</i> 1998	Tiopronin (800-1,200 mg/day), D-penicillamine (1000-2000gm/day), captopril (50 mg 3 times day)	NR	NR	NR	87	Decreased stone recurrence rate when urinary cystine excretion <797 mg/gm creatinine/24 hours
DeBerardinis <i>et al.</i> 2008	D-penicillamine (5-20 mg/kg/day)	NR	Decreased by 54%	NR	NR	Decreased urinary cystine levels
Malieckal <i>et al.</i> 2019	Tiopronin, D-penicillamine	NS	Reduced 24 hours urinary cystine excretion, <i>p</i> <0.039	NR	NR	Decreased urinary cystine levels
Moore <i>et al.</i> 2018	D-penicillamine (500mg twice a day)	NR	NR	NR	63	Successful stone clearance was associated with decreased stone recurrence rate
Onal <i>et al.</i> 2013	Tiopronin (10 mg/kg/day)	NR	NR	NR	74	Tiopronin was recommended for cystine stone patients after stone analysis

Pietrow <i>et al.</i> 2003	Tiopronin (1000mg/day)	NR	154.3mg/L, $p=0.004$	0.5	NR	Decreased urinary cystine levels
Shim <i>et al.</i> 2014	D-penicillamine (250 mg twice a day)	NR	NR	3.2 during 5 years follow-up	64	64.3% of cystinuria patients were compliant with medical treatment resulting in significantly reduced residual stones
Strologo <i>et al.</i> 2007	Tiopronin (25 mg/kg/day), D-penicillamine (17mg/kg/day)	NR	NR	Stone events decreased from 0.28 to 0.03	NR	Decreased stone events per patient
Tekin <i>et al.</i> 2001	Tiopronin (10-15 mg/kg/day)	5.6±0.2-6.9±0.3, $p=0.020$	245±266 mmol/mol.creatinine and 140±106 mmol/mol.creatinine, $p=0.015$	NR	67	Decreased urinary cystine levels

Table 6. Effectiveness of surgical interventions

Study	Interventions	Stone position	Stone events per patient	Surgical procedures per patient	Surgical procedures per patients-year	Stone-free rate (%)	Stone recurrence rate (%)	Key outcomes
Ahmed <i>et al.</i> 2008	ESWL, PCNL, URS, OP	NR	4.2	7.9	NR	93	NR	Repeated surgical procedures were required even with pharmacological intervention
Barbey <i>et al.</i> 2000	SWL, PCNL, RIRS, OP	22% unilateral and 30% bilateral	2.4	1.5	0.14 vs 0.29, $p<0.01$	22	78	Number of surgical procedures decreased after pharmacological intervention
Chow <i>et al.</i> 1996	ESWL, PCNL, RIRS	75% unilateral and 13% bilateral	5.5	0.84	0.3	75	NR	Stone events and interventions decreased when alkalization and thiols were used
Chow <i>et al.</i> 1998	ESWL, PCNL, RIRS, PCNL+ESWL	NR	NR	1.98	NR	87	68	Stone free recurrence probability was higher at 1 year than 5 years after first surgical procedure
Moore <i>et al.</i> 2019	SWL, PCNL, URS	NR	NR	2.7	NR	NR	62.5	Stone recurrence rate and number of procedures were lower when patients achieved stone-free status in the first treatment
Onal <i>et al.</i> 2013	SWL, PCNL, URS, OP, PCNL+OP	46% left kidney and 54% right kidney	NR	NR	NR	63	31	PCNL was a safe and effective treatment for children with cystine stones
Pareek <i>et al.</i> 2005	SWL, PCNL, URS	NR	NR	1 per patient in complaint group, $p<0.05$	NR	73% of compliant patients	NR	Fewer numbers of surgical interventions were required with compliant patients

Shim <i>et al.</i> 2104	PCNL, URS, OP	Calyceal 41%, pelvic 4%, ureteral 55%	3.2	2.7	NR	64	NR	Surgical procedures were effective when alkalization and pharmacological treatment were also used
Tekin <i>et al.</i> 2001	ESWL, PCNL, URS, OP, ESWL+OP, ESWL+PCNL	NR	NR	NR	0.64	67	33	Residual stones after surgical intervention were linked to future stone recurrence
Trinchieri <i>et al.</i> 2007	ESWL, PCNL, OP	NR	NR	NR	1.34 vs 1.16	NR	0.111 vs 0.493	Both less invasive and traditional surgical procedures had similar treatment outcomes
Usawachintachit <i>et al.</i> 2018	SWL, PCNL, URS, OP	33% unilateral and 67% bilateral	NR	5	0.57	NR	NR	Higher numbers of surgical interventions were required for bilateral stones than unilateral stones
Varda <i>et al.</i> 2015	ESWL, PCNL, URS, OP	NR	NR	6	1	NR	NR	Staghorn stones had higher annual procedures than non-staghorn stones
Yuruk <i>et al.</i> 2017	RIRS	NR	NR	NR	NR	100%	NR	RIRS is a safe and effective treatment for pediatric cystine stones

1 **Table 7. Comparison between cystine and non-cystine stone patients**

Study	Interventions	Comparison	No. of surgical procedures (cystine vs non-cystine stones)	Serum creatinine (cystine vs non-cystine stones)	Stone size (mm) (cystine vs non-cystine stones)	Age (years) (cystine vs non-cystine stones)	Key outcomes
Assimos <i>et al.</i> 2002	ESWL, PCNL, OP	Cystine and CaOx stone patients	14.1% vs 2.96%, $p=0.007$	Higher serum creatinine levels in cystinuria patients, $P=0.0001$	NR	$P=0.00001$	Higher numbers of surgical procedures were required to remove cystine stones than CaOx stones
Sfoungaristos <i>et al.</i> 2015	ESWL, PCNL, URS, RIRS	Cystine and CaOx stone patients	9.80±9.17 vs 2.73±1.95, $p<0.001$	110.97±50.4mmol/L vs 80.7±18.9mmol/L, $p<0.005$	Larger in size, 24.6±11.0mm vs 15.2±8.2mm, $p<0.001$	Early age, 15.0±11.1 vs 33.5±14.8, $p<0.001$	Cystine stones were larger than CaOx stones in size and present at an earlier age
Worcester <i>et al.</i> 2006	Potassium citrate D-penicillamine or Captopril, Tiopronin SWL	Cystine and non-cystine stone patients	Before therapy (4.0 vs 1.86, $p<0.001$) and after therapy (0.88 vs 0.23, $p<0.001$)	NR	NR	NR	A higher number of surgical procedures were required for treatment of cystine stones compared to non-cystine stones
Yamacake <i>et al.</i> 2016	PCNL, SWL and OP	Cystine and struvite stone patients	3.57±1.04 and 2.0±1.22, $p=0.028$	1.05±0.65mg/dL and 0.98±0.53mg/dL, $p=0.601$	NR	NR	A higher number of stone-free procedures were required for cystine stone patients than struvite stone patients

2 SWL/ESWL, extracorporeal shockwave lithotripsy; PCNL, percutaneous nephrolithotomy; RIRS, retrograde intrarenal surgery; URS,
3 ureterorenoscopy; OP, open surgery; CaOx, calcium oxalate; NR, not reported; NS, not significant

4